Treatment of breast cancer with gonadotrophin-releasing hormone analogues - preclinical studies with Zoladex, B.J.A. Furr, et al; clinical pharmacology of LHRH agonists (Zoladex) in breast cancer, R.I.Nicholson; GnRH agonist Zoladex treatment in pre- and perimenopausal women with metastatic breast cancer - a review of the international experience, M. Kaufmann; combined LHRH agonist (Zoladex) and tamoxifen therapy in premenopausal advanced breast cancer, A.R. Dixon, et al; an LHRH analogue in early breast cancer - clinical trial programme, K.L. Simpson; feasibility of tamoxifen in the chemoprevention of breast cancer, A.L. Jones; prognosis in none-negative breast cancer, S.M. O'Reilly, et al; hormone treatment of locally advanced breast cancer, N.C. Armitage; a review of treatment of locoregional breast cancer in older women, P.E. Preece and J.M. Horobin; systemic risk-adapted adjuvant treatment of patients with stage II breast cancer, H.E. Eidtmann, et al; the Christie Hospital adjuvant tamoxifen (Nolvadex) breast trial - an analysis at a maximum follow-up of 13 years, G. Ribeiro and R. Swindell; the Tenovus Lecture - oestrogen deprivation in breast cancer, R.I. Nicholson; therapeutic potential of pure antioestrogens in the treatment of breast cancer, A.E. Wakeling.
